Latest On H. Lundbeck A/S (HLUKF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-13 23:48 EST | News | H Lundbeck A/S (HLUKF) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-13 23:48 EST | News | H. Lundbeck A/S 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-02-09 05:16 EST | News | H Lundbeck A/S (HLUKF) Q4 2022 Earnings Call Transcript | N/A | |
| 2022-11-12 15:37 EST | News | H Lundbeck A/S (HLUKF) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-09 17:05 EST | News | H. Lundbeck A/S Non-GAAP EPS of DKK0.69, revenue of DKK4.72M | N/A | |
| 2022-08-18 04:24 EST | News | H Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-17 11:08 EST | News | H. Lundbeck A/S GAAP EPS of DKK0.92, revenue of DKK8.84B | N/A | |
| 2022-06-27 20:25 EST | News | Lundbeck, Otsuka drug helps reduce agitation in Alzheimer’s dementia patients in trial | N/A | |
| 2022-03-24 06:01 EST | Dividend | A dividend of $2 has been announced on Feb 9, 2022. It will be paid Mar 28, 2022 with an ex-dividend date of Mar 24, 2022. | Neutral | |
| 2022-02-10 20:10 EST | News | H. Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-10 00:19 EST | News | H. Lundbeck A/S GAAP EPS of DKK6.63, revenue of DKK16.3B | N/A | |
| 2021-11-11 17:55 EST | News | H. Lundbeck A/S 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-11-10 21:11 EST | News | H. Lundbeck A/S reports Q3 results | N/A | |
| 2021-11-10 21:10 EST | News | H. Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-19 19:17 EST | News | H. Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-19 19:17 EST | News | H. Lundbeck A/S 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-08-18 22:01 EST | News | H. Lundbeck A/S | N/A | |
| 2021-03-24 06:04 EST | Dividend | A dividend of $2.5 has been announced on Nov 30, -0001. It will be paid Mar 26, 2021 with an ex-dividend date of Mar 24, 2021. | Neutral | |
| 2021-02-06 05:12 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-05 19:16 EST | News | H. Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-05 01:25 EST | News | H. Lundbeck A/S reports FY results | N/A | |
| 2021-02-05 01:25 EST | News | H. Lundbeck A/S 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-01-12 17:12 EST | News | Lundbeck's migraine med OK'd in Canada | N/A | |
| 2020-11-26 23:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-10 01:48 EST | News | H. Lundbeck A/S 2020 Q3 - Results - Earnings Call Presentation | N/A | |
| 2020-11-08 02:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 05:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 05:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-04 18:14 EST | News | H Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-03 16:14 EST | News | H. Lundbeck A/S reports 9M results | N/A | |
| 2020-09-26 15:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-17 06:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 08:19 EST | News | H. Lundbeck A/S reports Q2 results | N/A | |
| 2020-08-14 08:19 EST | News | H. Lundbeck A/S 2020 Q2 - Results - Earnings Call Presentation | N/A | |
| 2020-08-14 08:19 EST | News | H. Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-06 14:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 11:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 02:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:53 EST | Financials | Company financials have been released. | Neutral | |
About H. Lundbeck A/S (HLUKF):
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; Vyepti for migraine prevention; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. The company was founded in 1915 and is headquartered in Valby, Denmark.
General
- Name H. Lundbeck A/S
- Symbol HLUKF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 5,628
- Fiscal Year EndDecember
- Web URLhttp://www.lundbeck.com
View More
Valuation
- Trailing PE 11.87
- Forward PE 20
- Price/Sales (Trailing 12 Mt.) 2.64
- Price/Book (Most Recent Quarter) 2.75
- Enterprise Value Revenue 0.46
- Enterprise Value EBITDA 1.67
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 9%
- Return on Assets 5%
- Return on Equity 9%
- Earnings Per Share $3.00
- Revenue Per Share $0
- Gross Profit 13.55 billion
- Quarterly Earnings Growth -3.3%
View More
ESG Rating
Highlights
- Market Capitalization 6.75 billion
- PEG Ratio 1.17
- Book Value Per Share $10.65
View More
Share Statistics
- Shares Outstanding 198.71 million
- Shares Float 61.21 million
- % Held by Insiders <1%
- % Held by Institutions 80.88%
View More
Technicals
- Beta 0.56
- 52 Week High $43.17
- 52 Week Low $26.25
- 50 Day Moving Average 38.85
- 200 Day Moving Average 34.01
View More
Dividends
- Forward Annual Dividend Rate $0.4
- Forward Annual Dividend Yield 1.04%
- Payout Ratio 63%
- Dividend Date 2012-04-04
- ExDividend Date 2021-03-24
- Dividend Per Share $1.25
- Dividend Yield 0%
View More
H. Lundbeck A/S (HLUKF) Dividend Calendar:
HLUKF's last dividend payment was made to shareholders on April 4, 2012.
H. Lundbeck A/S pays out 63% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
H. Lundbeck A/S (HLUKF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $4.28 billion | $0.45 | ||
| 2020-09-30 | 2020-12-31 | $4.46 billion | $0.31 | ||
| 2020-06-30 | 2020-09-30 | $N/A | $0.37 | $1.95 | -80.82% |
| 2020-03-31 | 2020-06-30 | $4.56 billion | $0.44 | $2.42 | -81.76% |
| 2019-12-31 | 2020-03-31 | $N/A | $0.11 | $0.57 | -80.32% |
| 2019-09-30 | 2019-12-31 | $603.67 million | -$0.09 | $4.00 | -102.36% |
| 2019-06-30 | 2019-09-30 | $642 million | $0.55 | $4.33 | -87.26% |
| 2019-03-31 | 2019-06-30 | $635.97 million | $0.60 | $4.22 | -85.7% |
| 2018-12-31 | 2019-03-31 | $644.43 million | $0.68 | $3.30 | -79.42% |
| 2018-09-30 | 2018-12-31 | $719.4 million | $0.51 | $5.33 | -90.53% |
| 2018-06-30 | 2018-09-30 | $734.6 million | $0.83 | $4.78 | -82.71% |
| 2018-03-31 | 2018-06-30 | $757.19 million | $0.79 | $4.52 | -82.57% |
| 2017-12-31 | 2018-03-31 | $708.19 million | $1.00 | $3.38 | -70.52% |
| 2017-09-30 | 2017-12-31 | $685.39 million | $0.45 | $3.44 | -86.96% |
| 2017-06-30 | 2017-09-30 | $4.28 billion | $0.70 | $2.92 | -76.01% |
| 2017-03-31 | 2017-06-30 | $4.21 billion | $0.47 | $3.05 | -84.52% |
| 2016-12-31 | 2017-03-31 | $4.17 billion | $0.42 | $1.63 | -73.96% |
| 2016-09-30 | 2016-12-31 | $0.34 | $1.23 | -72.43% | |
| 2016-06-30 | 2016-09-30 | $0.24 | $1.09 | -77.56% | |
| 2016-03-31 | 2016-06-30 | $0.18 | $1.33 | -86.79% | |
| 2015-12-31 | 2016-03-31 | $0.14 | $0.73 | -80.32% | |
| 2015-09-30 | 2015-12-31 | -$0.33 | -$6.84 | 95.17% | |
| 2015-06-30 | 2015-09-30 | -$0.96 | -$0.92 | -4.11% | |
| 2015-03-31 | 2015-06-30 | -$2.97 | $0.08 | -3810.38% | |
| 2014-12-31 | 2015-03-31 | -$0.06 | -$2.40 | 97.53% | |
| 2014-09-30 | 2014-12-31 | -$0.52 | -$0.24 | -118.25% | |
| 2014-06-30 | 2014-09-30 | $0.00 | $0.95 | -99.55% | |
| 2014-03-31 | 2014-06-30 | $0.13 | |||
| 2013-12-31 | 2014-03-31 | $0.31 | |||
| 2013-09-30 | 2013-12-31 | $0.02 | |||
| 2013-06-30 | 2013-09-30 | $0.25 | |||
| 2013-03-31 | 2013-06-30 | -$0.45 | |||
| 2012-12-31 | 2013-03-31 | $0.93 | |||
| 2012-09-30 | 2012-12-31 | $0.18 | |||
| 2012-06-30 | 2012-09-30 | $0.37 | |||
| 2012-03-31 | 2012-06-30 | -$0.07 | |||
| 2011-12-31 | 2012-03-31 | $0.57 | |||
| 2011-09-30 | 2011-12-31 | $0.18 | |||
| 2011-06-30 | 2011-09-30 | $0.32 | |||
| 2011-03-31 | 2011-06-30 | $0.79 | |||
| 2010-12-31 | 2011-03-31 | $0.90 | |||
| 2010-09-30 | 2010-12-31 | $0.22 | |||
| 2010-06-30 | 2010-06-30 | $0.58 | |||
| 2010-03-31 | 2010-03-31 | $0.89 | |||
| 2009-12-31 | 2009-12-31 | $0.24 | |||
| 2009-09-30 | 2009-09-30 | $0.59 | |||
| 2009-06-30 | 2009-06-30 | $0.44 | |||
| 2009-03-31 | 2009-03-31 | $0.62 | |||
| 2008-12-31 | 2008-12-31 | $0.01 | |||
| 2008-09-30 | 2008-09-30 | $0.65 | |||
| 2008-03-31 | 2008-03-31 | $0.63 |
H. Lundbeck A/S (HLUKF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 883 million | 951 million | N/A | 1.67 billion | N/A |
| Income Before Tax | 192 million | 629 million | N/A | 241 million | N/A |
| Selling General Administrative | 1.93 billion | 1.61 billion | N/A | 1.72 billion | N/A |
| Gross Profit | 3.03 billion | 3.27 billion | N/A | 3.76 billion | N/A |
| Ebit | 295 million | 701 million | N/A | 338 million | N/A |
| Operating Income | 204 million | 701 million | N/A | 338 million | N/A |
| Income Tax Expense | -184 million | N/A | 262 million | N/A | N/A |
| Total Revenue | 4.28 billion | 4.46 billion | N/A | 4.56 billion | N/A |
| Cost of Revenue | 1.25 billion | 1.2 billion | N/A | 805 million | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | N/A |
| Net Income From Continuing Operations | 376 million | 472 million | N/A | 151 million | N/A |
| Net Income Applicable to Common Shares | 376 million | N/A | 582 million | N/A | N/A |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -140 million | N/A | -68 million | N/A | -145989.66 |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | N/A | -48 million | N/A | N/A | -16.64 million |
| Net Borrowings | N/A | -341 million | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | -2.77 million |
| Change to Operating Activities | N/A | 457 million | N/A | N/A | 23.5 million |
| Change in Cash | 490 million | N/A | -716 million | N/A | 179.86 million |
| Total Cash from Operating Activities | 1.18 billion | 1.41 billion | 188 million | N/A | 199.28 million |
| Depreciation | N/A | N/A | N/A | N/A | 44.67 million |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | -50 million | N/A | N/A | -2.77 million |
| Change to Net Income | N/A | -225 million | N/A | N/A | 21.46 million |
| Capital Expenditures | 127 million | N/A | 68 million | N/A | 16.5 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 19.06 billion | N/A | N/A | 20.79 billion | N/A |
| Total Stockholder Equity | 16.97 billion | N/A | N/A | 14.07 billion | N/A |
| Other Current Liabilities | 4.2 billion | 4.31 billion | N/A | N/A | N/A |
| Total Assets | 36.03 billion | N/A | N/A | 34.87 billion | N/A |
| Common Stock | 996 million | 996 million | 996 million | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | 15.75 billion | 13.14 billion | 12.66 billion | 12.1 billion | N/A |
| Other Liabilities | 3.23 billion | 2.11 billion | 2.15 billion | N/A | N/A |
| Other Assets | 337 million | N/A | N/A | N/A | N/A |
| Cash | 3.92 billion | N/A | N/A | 2.28 billion | N/A |
| Total Current Liabilities | 10.01 billion | 8.1 billion | N/A | 7.87 billion | N/A |
| Other Stockholder Equity | 229 million | 542 million | 838 million | N/A | N/A |
| Property, Plant & Equipment | 2.73 billion | 2.65 billion | 2.64 billion | N/A | N/A |
| Total Current Assets | 10.11 billion | 9.87 billion | N/A | 8.66 billion | N/A |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | -5.77 billion | -6.33 billion | -7.46 billion | N/A | N/A |
| Short Term Investments | N/A | N/A | N/A | 4 million | N/A |
| Long Term Debt | 5.4 billion | N/A | N/A | N/A | N/A |
| Inventory | 2.16 billion | 2.21 billion | N/A | 2.35 billion | N/A |
| Accounts Payable | 3.74 billion | 3.58 billion | N/A | 3.63 billion | N/A |
H. Lundbeck A/S (HLUKF) Chart:
H. Lundbeck A/S (HLUKF) News:
Below you will find a list of latest news for H. Lundbeck A/S (HLUKF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
H. Lundbeck A/S (HLUKF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
H. Lundbeck A/S (HLUKF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|